While industry eagerly awaits the Supreme Court's review of the biosimilars statute, companies are making various maneuvers in ongoing litigation.
Genentech Inc. was blocked in its move to get Amgen Inc. to turn over manufacturing process information for its biosimilar to Genentech's monoclonal antibody Avastin (bevacizumab), ABP 215. In a March 1